New blood tests may help doctors detect Alzheimer’s disease earlier. These tests could be faster, cheaper, and less invasive than current methods. But some worry about diagnosing people who may never show symptoms.
The Challenge of Early Diagnosis
Chris noticed small memory lapses in his mother. At first, he thought the issues were just video call glitches. But when she got lost in her own home, he realized something was wrong. She was diagnosed with Alzheimer’s at 67 after taking a simple cognitive test. She never saw a neurologist. Sadly, many people with Alzheimer’s face similar situations. The most reliable methods for diagnosing Alzheimer’s are brain scans or spinal fluid tests. However, these tests are expensive, and many patients can’t access them. In the UK, only 2% of dementia patients receive these tests, according to Alzheimer’s Research UK.
Blood Tests: A Game-Changer?
New blood tests for Alzheimer’s could change everything. They are less expensive, faster, and easier to use than brain scans or spinal tests. Researchers have already started trials of these tests. They hope to get results within five years. These tests look for certain proteins in the blood, such as p-tau217. This protein is closely linked to Alzheimer’s.
These blood tests are especially important now. New drugs like lecanemab and donanemab can lower amyloid levels in the brain. While these drugs offer only small benefits, they may work better if given early, before symptoms appear. Treating Alzheimer’s earlier could delay or prevent the disease from progressing.
The Debate Over Diagnosing “Preclinical” Alzheimer’s
There is a big debate about whether we should use blood tests to diagnose Alzheimer’s in people who don’t show any symptoms. The US Alzheimer’s Association suggested diagnosing people based only on the presence of certain biomarkers, even in those without symptoms. This idea has sparked criticism from experts.
Some researchers, like the European International Working Group, say that many people with amyloid in their brains will never develop dementia. These people may not need a diagnosis, and labeling them could cause unnecessary stress.
Dr. Nicolas Villain, a neurologist, warns that this change would dramatically increase the number of Alzheimer’s patients. It would also change the way we think about the disease. Right now, Alzheimer’s is seen as irreversible. If we diagnose based on biomarkers, we would create a “gray area” for people who might never get sick. These people could be given the label of “potential” Alzheimer’s patients, which adds confusion.
Timothy Daly, a bioethicist, agrees. He believes that labeling healthy people as “potential patients” would make the situation even more complicated. It could also create fear and uncertainty.
What Experts Say About Blood Tests
For now, many experts advise against using blood tests to diagnose people without symptoms. Jonathan Schott from Alzheimer’s Research UK suggests that the tests should be used mainly in clinical trials. Blood tests can show if a person is at risk for Alzheimer’s, but they can’t say for sure whether someone will develop the disease.
Schott explains that we don’t yet know how many people with biomarkers will go on to develop Alzheimer’s. So, using the tests outside of clinical trials could cause problems. “A blood test alone is not enough to predict dementia,” Schott says.
Researchers are still learning about how blood tests can help. They need more data to understand which biomarkers are the most important. The goal is to figure out who will develop Alzheimer’s and when. This knowledge will help doctors decide when to treat people.
The Future of Alzheimer’s Testing
The future of Alzheimer’s testing looks promising, but we still have a long way to go. Blood tests could eventually become a valuable tool for early detection. However, they are not perfect. For now, these tests show risk, not certainty. Experts stress that we must be careful with how we use these tests.
The goal is to identify people who will develop Alzheimer’s before symptoms appear. But we must also be mindful of the risks of diagnosing too early. Labeling people who might never develop symptoms could cause unnecessary worry. It could also confuse both doctors and patients.
For now, the focus remains on clinical trials. As research continues, we will learn more about how these tests work. In the meantime, early detection and treatment remain key to managing Alzheimer’s disease.
For more information on Alzheimer’s research and news, visit New York Mirror.